©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jun 27, 2021; 13(6): 516-528
Published online Jun 27, 2021. doi: 10.4240/wjgs.v13.i6.516
Published online Jun 27, 2021. doi: 10.4240/wjgs.v13.i6.516
Borderline resectable pancreatic cancer: Certainties and controversies
Gennaro Nappo, Greta Donisi, Alessandro Zerbi, Pancreatic Surgery Unit, Humanitas Clinical and Research Center-IRCCS, Rozzano 20089, Italy
Author contributions: Nappo G and Zerbi A contributed to the conception and design of the study; Nappo G, Donisi G and Zerbi A drafted and critically revised the manuscript and approved the final version of the article; Nappo G and Zerbi A are directly responsibility for the manuscript.
Conflict-of-interest statement: None of the authors have conflicts of interest.
Corresponding author: Gennaro Nappo, MD, Surgeon, Pancreatic Surgery Unit, Humanitas Clinical and Research Center-IRCCS, Via Manzoni 56, Rozzano 20089, Italy.
Received: February 28, 2021
Peer-review started: February 28, 2021
First decision: April 6, 2021
Revised: April 9, 2021
Accepted: May 25, 2021
Article in press: May 25, 2021
Published online: June 27, 2021
Processing time: 109 Days and 21.3 Hours
Peer-review started: February 28, 2021
First decision: April 6, 2021
Revised: April 9, 2021
Accepted: May 25, 2021
Article in press: May 25, 2021
Published online: June 27, 2021
Processing time: 109 Days and 21.3 Hours
Core Tip
Core Tip: The term borderline resectable identifies a tumour with an aggressive biological behaviour, on which a neoadjuvant approach instead of upfront surgery one should be preferred, in order to obtain a radical resection (R0) and to avoid an early recurrence after surgery. The aim of this review is to critically analyse the available literature on this topic.